Better CD33-targeted treatments for acute myeloid leukemia
Official title: Optimizing the Efficacy and Safety of CD33-Targeted Immunotherapy for Acute Myeloid Leukemia and Other CD33+ Disorders
Funded at Fred Hutchinson Cancer Center · NIH-11141116 · Data updated 2026-11-12
Researchers are developing new CD33-targeted antibody therapies paired with a potent alpha-particle agent to help people with acute myeloid leukemia.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Fred Hutchinson Cancer Center NIH-funded |
| Lab location | 1 site (Seattle, United States) |
| Project start | August 15, 2023 |
| Project end | July 31, 2028 |
| Funding year | 2025 |
| Award (this year) | $161,878 |
| NIH project number | 5R50CA274319-03 |
| Project ID | NIH-11141116 on NIH RePORTER |
Who could benefit from this research
✓Could help
People with CD33-positive acute myeloid leukemia—particularly those with relapsed or treatment-resistant disease—would be the most likely candidates for future trials.
✕Less likely to help
Patients whose leukemia does not express CD33 or who cannot tolerate targeted radiation approaches would be unlikely to benefit from this work.
What this research studies
If you have AML, this work focuses on new antibodies that bind a different part of the CD33 protein found on leukemia cells. The team will attach a tiny but powerful radioactive particle (astatine-211) to those antibodies to deliver focused radiation directly to cancer cells. They will run lab experiments and animal studies to find the safest and most effective antibody designs and dosing that spare normal blood cells. The goal is to prepare the best approaches for testing in patients at their center.
Why it matters
Potential benefit: Could produce more effective and safer CD33-directed treatments that kill AML cells while reducing harm to normal blood cells.
How similar studies have gone: An earlier CD33 drug (gemtuzumab ozogamicin) improved outcomes for some AML patients, but many CD33-directed approaches have failed, and combining new CD33 antibodies with astatine-211 is a newer, mostly preclinical strategy.
Where this research is happening
-
Fred Hutchinson Cancer Center
Seattle, United States Active
Researchers
- Principal investigator: Laszlo, George S — Fred Hutchinson Cancer Center
- Study coordinator: Laszlo, George S
Related research
Other NIH-funded projects on the same topics.
-
CD33-targeted immunotherapy to help AML patients
A patient-focused approach tests new antibody-drug strategies that target CD33 to improve safety and effectiveness for AML patients.
-
Myeloid-targeted oligonucleotide STAT3 blocker with TMLI for AML treatment
A new approach combines targeted radiation with a special gene-silencing treatment to help people with treatment-refractory acute myeloid leukemia.
-
Improving treatment for acute myeloid leukemia with targeted radiation and immune therapy
This work explores a new way to treat acute myeloid leukemia that has been difficult to cure, by combining a special type of radiation with a targeted immune therapy.
-
Improving treatment for acute myeloid leukemia using targeted immunotherapy
This study is looking at new ways to make immunotherapy better and safer for people with acute myeloid leukemia (AML) by developing special antibodies that target a protein called CD33, and it aims to help improve treatment results while protecting healthy cells.
-
Targeting specific immune cells to improve treatment for acute myeloid leukemia
This study is testing a new way to treat acute myeloid leukemia (AML) by using a special combination of targeted treatments that block a protein called STAT3 along with a type of radiation therapy, to see if it can help improve survival for patients whose cancer hasn't responded to other treatments.
-
Targeting the SCP4 pathway in acute myeloid leukemia (AML)
Aims to uncover how the SCP4 signaling pathway drives AML and how it could be blocked to help patients.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.